PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug candidate BR101801 tested in advanced blood cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:53 UTC